




Contents lists available at ScienceDirect

Prostate International

journal homepage: <https://www.journals.elsevier.com/prostate-international>

## Original Article

## The effect of prostatic inflammation on clinical outcomes in patients with benign prostate hyperplasia

Suleyman Sami Cakir <sup>a,\*</sup>, Emre Can Polat <sup>a</sup>, Levent Ozcan <sup>b</sup>, Huseyin Besiroglu <sup>c</sup>, Alper Ötunctemur <sup>a</sup>, Emin Ozbek <sup>d</sup><sup>a</sup> Okmeydani Training and Research Hospital, Department Urology, Istanbul, Turkey<sup>b</sup> Derince Training and Research Hospital, Department of Urology, Kocaeli, Turkey<sup>c</sup> Catalca State Hospital, Department Urology, Istanbul, Turkey<sup>d</sup> Istanbul Training and Research Hospital, Department Urology, Istanbul, Turkey

## ARTICLE INFO

## Article history:

Received 12 June 2017

Received in revised form

9 November 2017

Accepted 23 December 2017

Available online xxx

## Keywords:

Benign prostatic hyperplasia  
International prostate symptom score  
Prostatic inflammation  
Prostate pathology  
Trans urethral resection of the prostate

## ABSTRACT

**Background:** To investigate the effect of asymptomatic inflammatory prostatitis on clinical outcomes of patients undergoing trans urethral resection of prostate due to benign prostatic hyperplasia.**Materials and methods:** A total of 514 patients were enrolled in the study. Clinical parameters and pathological results were compared before and one year after surgery.**Results:** Of the patients 310 were diagnosed with purely benign prostatic hyperplasia and the others were diagnosed with both prostatic inflammation (category IV) and benign prostatic hyperplasia. No statistical significance was observed between two groups among the parameters including age, prostate volume and post voiding residue ( $P > 0.05$ ). Patients with prostate inflammation presented higher preoperative International Prostate Symptom Score and lower Qmax values when compared to those without inflammation before trans urethral resection of prostate.**Conclusion:** Asymptomatic prostate inflammation can lead to worsen lower urinary tract symptoms and urinary flow rate in patients with benign prostatic hyperplasia. Furthermore, the improvement of the complaints after surgery was worse in patients with asymptomatic prostate inflammation. Further well designed prospective-randomised studies are needed to support our findings.© 2018 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## 1. Introduction

Benign prostatic hyperplasia (BPH), which is defined as hyperplasia in stroma and glands of prostate histologically, is a common benign neoplasm in men after the age of 50 years.<sup>1</sup> It is characterized by the lower urinary tract symptoms (LUTS) and bladder outlet obstruction. LUTS result from several diseases but benign prostatic enlargement is the leading cause and more than 50% of men aged above 50 years are believed to experience LUTS secondary to an enlarged prostate gland.<sup>2–4</sup>

Although BPH/LUTS are likely to cause an even heavier burden on health-care systems, the pathogenesis of this condition is still largely unknown. Many factors are likely to be involved in the development and progression of prostate enlargement. Epidemiological and histopathological studies have indicated the possible role of prostate inflammation in the pathogenesis of LUTS and BPH.<sup>5</sup>

Histological evidence of prostatic inflammation is investigated in patients with BPH who do not have symptoms of prostatitis. Asymptomatic prostate inflammation is acknowledged in the National Institute of Health (NIH) classification of prostatitis (category IV) and has been detected in 43–98% of surgically resected prostatic tissues removed for BPH.<sup>6</sup> The standardized classification system of chronic prostatitis and chronic pelvic pain syndrome which was proposed by Nickel et al in 2001 can be used in the evaluation of prostatic inflammation in prostate biopsies, transurethral resected prostatic tissues, or prostatectomy specimens.<sup>7</sup> The purpose of the present study was to compare the effect of prostatic inflammation on the outcomes of clinical parameters of the patients undergoing transurethral resection of the prostate (TURP) due to BPH.

## 2. Materials and methods

After receiving approval of an Ethics Committee of the Okmeydani Training and Research Hospital, Istanbul, Turkey, the records of patients who underwent TURP due to BPH were examined

\* Corresponding author. Okmeydani Training and Research Hospital, Department of Urology, 34384, Sisli, Istanbul, Turkey.

E-mail address: [ssamicakir@hotmail.com](mailto:ssamicakir@hotmail.com) (S.S. Cakir).

<https://doi.org/10.1016/j.pnil.2017.12.003>

p2287-8882 e2287-903X/© 2018 Asian Pacific Prostate Society, Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

retrospectively between 2013 and 2015. After scanning the data of the patients, a total of 514 patients were included in the study along with clinical information and histopathological results.

Inclusion criteria were identified as follows: patients with LUTS due to BPH admitted to urology clinic, over the age of 50 years, with no previous urologic surgery. Patients were excluded from the study if they had positive urine culture, chronic pelvic pain syndrome diagnosed according to the NIH classification (category III prostatitis), acute and chronic bacterial prostatitis bladder or prostate cancer, bladder stone, urethral stenosis, and neurological diseases. After the medical data screening conducted according to these criteria, 514 patients were defined as BPH. Among them 86 patients (17%) underwent catheterization due to acute urinary retention, and 204 patients (40%) had prostatic inflammation (category IV prostatitis). BPH was diagnosed with digital rectal examination, micturition symptoms, and transrectal guided ultrasound. All patients received alpha-blocker therapy for at least 3 months before TURP except those with a urethral catheter.

Information of the patients, such as weight, height, blood pressure, medical history of hypertension, diabetes, serum prostate specific antigen (PSA) levels, maximal urine flow (Qmax), and post voiding residue (PVR), was collected when the patients were admitted to the urology clinic. Prostate volume was calculated by transrectal ultrasonography. International Prostate Symptom Score (IPSS) had been surveyed by questionnaire before TURP and 1 year after TURP, respectively.<sup>8</sup>

Prostate inflammation was determined by evaluation the samples obtained from TURP. Inflammatory cells infiltration within BPH tissue was defined according to the histopathological classification system of prostatic inflammation reported by Nickel et al which evaluated prostatic inflammation for location (glandular, periglandular, and stromal), extent (focal, multifocal, and diffuse) and grade (mild, moderate, and severe).<sup>7</sup>

### 2.1. Statistical analysis

The normality test was performed using Kolmogorov–Smirnov test. Mann–Whitney U or Student *t* test was performed comparing continuous variables between the two groups according to normality test.  $\chi^2$  test was performed for categorical variables. All analyses were performed using SPSS, version 19 (SPSS Inc., Chicago, IL, USA). All demographic values were presented as means with standard deviations. All tests for statistical significance were 2-tailed, and  $P < 0.5$  was deemed significant.

## 3. Results

Overall 514 patients were retrospectively enrolled. All patients underwent TURP. Of the participants, 310 were diagnosed with BPH alone, and the others were diagnosed with both prostatic

inflammation (category IV) and BPH. A urethral catheter was inserted into 36 patients with BPH alone (7%) and 50 patients with prostatic inflammation/BPH (10%), respectively.

The age range of patients was between 50 and 81 years (median 68 years); the average of the prostate volume was 59 ml (33–90). Patients' characteristics such as age, PVR, prostate volume, and PSA are summarized in Table 1. All patients were treated with TURP. The mean operation time was  $64.3 \pm 24.5$  minute, and the average catheterization time was  $3.6 \pm 1.2$  days. Thirty-three patients had postoperative complications (transient hematuria in 14 patients, urinary retention resolved by recatheterizations in 11 patients and urinary tract infections in 8 patients). No conversion to open surgery in any case and no TURP-related death was recorded during the study period.

Patients were divided into two groups depending on whether they were catheterized preoperatively or not. Then, both groups were divided into two in itself according to the presence of prostatic inflammation or not. No statistical significance was observed among the patients in terms of age, prostate volume, and PVR ( $P > 0.05$ ). However, PSA level of the BPH/prostatic inflammations group was significantly higher than the BPH alone group:  $3.8 \pm 4.4$  ng/dl (0.16–7.2) versus  $2.5 \pm 1.8$  ng/dl (0.25–6.2),  $P = 0.001$ , before TURP. Patients with prostate inflammation presented higher preoperative urethral catheterization rate when compared to those without inflammation (50 of 204 patients with BPH/prostate inflammation vs. 36 of 310 patients with BPH alone, 11.6%, 24.5%, respectively,  $P < 0.05$ ) (Table 1).

Overall, 310 of 514 patients (60.3%) showed no sign of prostate inflammation at the histology report, whereas 204 of 510 patients (39.7%) presented an inflammatory infiltrate. Inflammation was mild in 107 of 204 (52.5%) patients, moderate in 82 of 204 (40.2%) patients, and severe in 15 of 204 (7.1%) patients according to the histopathological classification system. Anatomic location of prostate inflammation occurred within stromal (47.4%), glandular (21.4%), and periglandular (31.1). Regarding inflammatory infiltration extent, focal region infiltration occurred in 101 patients (49.3%), multifocal zone infiltration took place in 57 patients (27.9%), and diffuse area infiltration occurred in 46 patients (22.7%) (Table 3).

Patients with prostate inflammation presented higher (worse) preoperative IPSS and lower Qmax scores when compared to those without inflammation before TURP ( $29.9 \pm 9$ , five vs.  $23 \pm 5.3$  and  $6.2 \pm 1.9$  vs.  $8.4 \pm 1.9$ , respectively,  $P < 0.05$ ). In the same way, statistically significant differences in total IPSS scores and Qmax scores were found 1 year after TURP ( $P < 0.05$ ) (Table 2). No differences were observed between patients with mild and moderate-to-severe inflammation.

## 4. Discussion

In the last few years, several studies have examined the relationship between BPH and prostate inflammation. Epidemiological

**Table 1**  
Baseline patient characteristics before and 1 year after TURP

| Total (n = 514)                         | BPH*               | BPH/prostatic inflammation (category IV)* | P     |
|---|--------------------|---|-------|
| Before TURP                             | (n = 274)          | (n = 154)                                 |       |
| Age (year)                              | 65.9 ± 6.7         | 67.1 ± 7.4                                | 0.81  |
| Serum PSA level (ng/dl)                 | 2.5 ± 1.8          | 3.8 ± 4.4                                 | 0.001 |
| Prostate volume (cm <sup>3</sup> )      | 57.5 ± 11.3        | 57.1 ± 6.8                                | 0.75  |
| Post voiding residue (ml)               | 65.3 (35.1–92.4)   | 71.9 (36.0–100.3)                         | 0.48  |
| 1 year after TURP                       | (n = 274)          | (n = 154)                                 |       |
| Prostate volume (cm <sup>3</sup> )      | 23.6 ± 9.5         | 25.4 ± 6.3                                | 0.64  |
| Post voiding residue (ml)               | 12.7 ± 4.3         | 14.0 ± 5.2                                | 0.67  |
| Catheterization/acute urinary retention | n = 36/310 (%11.6) | n = 50/154 (24.5%)                        | 0.002 |

BPH, benign prostatic hyperplasia; SD, standard deviation; TURP, transurethral resection of the prostate. Data are presented as mean ± SD or median interquartile range (IQR).

\*Patients with urethral catheter were not included in statistical analysis.

Download English Version:

<https://daneshyari.com/en/article/8829061>

Download Persian Version:

<https://daneshyari.com/article/8829061>

[Daneshyari.com](https://daneshyari.com)